drugset / Trial / NCT06439433
ALA-PDT in Patients With CIN2 in p16-positivity and High-risk HPV Infection
RandomizedParallel-groupQuadruple-blindTreatment
Summary
Efficacy and Safety of ALA-PDT in patients with cervical intraepithelial neoplasia grade 2 (CIN2) in p16-positivity and high-risk HPV infection.
Timeline
- Start
- 2021-05-31
- Primary completion
- 2023-12-20
- Completion
- 2024-03-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Aminolaevulinic acid | Unknown | 500 mg | — |
| Subject | Aminolaevulinic acid | Unknown | 750 mg | — |